The Catalyst

Most Recent Posts

08.20.13 | By Karl Uhlendorf

Bringing a medicine to patients, from discovery through FDA review, is a lengthy, costly and sometimes unpredictable process. On average, it takes 10-15 years and an investment of more than $1 billion. As noted previously on the Catalyst, only one out of 5,000-10,000 potential new medicines make it through the multiple and rigorous pre-clinical and clinical trials phases and is ultimately approved by the FDA for patient use.

08.16.13 | By John Castellani

Despite the great medical advances of the last century, there is still a lot of work to be done when it comes to developing medications and treatments to deal with neurological disorders such as Parkinson’s disease. These conditions pose vexing challenges for researchers trying to unlock the secrets that will improve the lives of millions living with the daily challenges that neurological diseases pose.

08.15.13 | By Dr. Bill Chin

As I read the Wall Street Journal’s article this week on gene breakthroughs in cancer treatment, I felt a range of emotions. First was excitement. Decades of devotion to research have taken science to new heights and it’s important that people are aware of the tremendous progress that has been made.

08.09.13 | By Gretta Stone

In case you missed it, a blog post and article published in Health Affairs by FDA officials earlier this week highlights 25 years of stead

08.06.13 | By Randy Burkholder

Last week, I highlighted a Hill briefing hosted by the Personalized Medicine Coalition and the great examples it provided of the impact of personalized medicine on patients. I was reminded why we must advocate for policies that support continued progress against disease and fulfill the promise of personalized medicine.

08.06.13 | By Sascha Haverfield, Ph.D.

Last week, the U.S. Food and Drug Administration (FDA) announced the prescription drug user fee rates for FY2014 –$2.169 million per application requiring clinical data review.  This reflects a significant increase of more than 10 percent over the FY2013 rates – and a twenty-fold increase in the user fees established in the Prescription Drug User Fee Act (PDUFA) of 1992.

08.05.13 | By Sascha Haverfield, Ph.D.

As noted in past Catalyst posts, the urgent need for new antibacterials is undisputed.  A recent article in Nature states that, “Health officials are watching in horror as bacteria become resistant to powerful carbapenem anti

08.02.13 | By Preet Bilinski

We recently released our Medicines in Development for Neurological Disorders report, which includes 38 medicines for multiple sclerosis (MS). It is a condition that impacts approximately 500,000 Americans. We recently had an opportunity to speak with Jodi Dwyer, a health activist who has MS and hope for a cure.

08.01.13 | By Matt Bennett

Biomedical research is behind the scientific advances that have helped increase the childhood cancer survivor rate and improve and lengthen the lives of people living with HIV/AIDs, heart disease and cancer.

08.01.13

As we approach the 10 year anniversary of Part D being signed into law, more good news recently came out of CMS about the program. Their data showed that average monthly premiums are projected to stay stable at $31 for the 2014 plan year. Additionally, the Part D deductible will decrease from $325 to $310 next year – creating more savings for beneficiaries.

08.01.13 | By Kaelan Hollon

How long do you think you’ll live? Do you feel like you had a pretty good health year thus far? What about your neighbors and those in your community – how’s their year been, health-wise? What cures do you think will be discovered next in medicine?

07.31.13 | By Preet Bilinski

The human brain, despite weighing just 3 pounds, contains over 100 billion neurons -- to say that it's complex is an understatement. These neurons are responsible for receiving messages and forwarding them to the appropriate parts of the brain, which in turn control everything we do.

07.30.13 | By Sascha Haverfield

The assessment of benefits and risks is critical in the development of new medicines.

07.30.13 | By John Castellani

Every person is unique, and so are the challenges they face when it comes to their health.

07.25.13 | By Randy Burkholder

On Monday, the Personalized Medicine Coalition convened leaders from the field on Capitol Hill to discuss the promise of personalized medicine and the implications for policy-makers. A number of important issues were raised (more on that in my next post), but the highlight was remarks by Stephanie Haney. Stephanie is a lung cancer patient and mother of two who said she is alive today thanks to a novel personalized medicine.

Pages